Literature DB >> 36066735

Increased myocardial extracellular volume is associated with myocardial iron overload and heart failure in thalassemia major.

Antonella Meloni1,2, Laura Pistoia1, Vincenzo Positano1,2, Antonio De Luca3, Nicola Martini1,2, Anna Spasiano4, Ilaria Fotzi5, Pier Paolo Bitti6, Domenico Visceglie7, Gianna Alberini8, Gianfranco Sinagra3, Alessia Pepe9, Filippo Cademartiri10.   

Abstract

OBJECTIVES: Myocardial extracellular volume (ECV) by cardiovascular magnetic resonance (CMR) is a surrogate marker of diffuse fibrosis. We evaluated the association between ECV and demographics, CMR findings, and cardiac involvement in patients with thalassemia major (TM).
METHODS: A total of 108 β-TM patients (62 females, 40.16 ± 8.83 years), consecutively enrolled in the Extension-Myocardial Iron Overload in Thalassemia Network, and 16 healthy subjects (6 females, 37.12 ± 16.13 years) underwent CMR. The protocol included assessment of T2*, native T1, and T2 values in all 16 myocardial segments for myocardial iron overload (MIO) quantification, cine images for left ventricular (LV) function quantification, post-contrast T1 mapping for ECV calculation, and late gadolinium enhancement (LGE) technique for replacement myocardial fibrosis detection.
RESULTS: Global ECV values were significantly higher in females than in males. Global ECV values were significantly higher in patients with significant MIO (global heart T2* < 20 ms) than in patients without significant MIO, and both groups exhibited higher global ECV values than healthy subjects. No association was detected between native T1 and ECV values, while patients with reduced global heart T2 values showed significantly higher global ECV values than patients with normal and increased global heart T2. Global ECV values were not correlated with LV function/size and were comparable between patients with and without LGE. Compared to patients without heart failure, patients with a history of heart failure (N = 10) showed significantly higher global heart ECV values.
CONCLUSION: In TM, increased myocardial ECV, potentially reflecting diffuse interstitial fibrosis, is associated with MIO and heart failure. KEY POINTS: • CMR-derived myocardial extracellular volume is increased in thalassemia major patients, irrespective of the presence of late gadolinium enhancement. • In thalassemia major, myocardial iron overload contributes to the increase in myocardial ECV, which potentially reflects diffuse interstitial fibrosis and is significantly associated with a history of heart failure.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Fibrosis; Heart failure; Iron overload; Magnetic resonance imaging; Thalassemia

Year:  2022        PMID: 36066735     DOI: 10.1007/s00330-022-09120-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  42 in total

1.  Iron in the heart. Etiology and clinical significance.

Authors:  L M Buja; W C Roberts
Journal:  Am J Med       Date:  1971-08       Impact factor: 4.965

2.  Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy.

Authors:  John C Wood; Maya Otto-Duessel; Michelle Aguilar; Hanspeter Nick; Marvin D Nelson; Thomas D Coates; Harvey Pollack; Rex Moats
Journal:  Circulation       Date:  2005-07-18       Impact factor: 29.690

3.  Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach.

Authors:  Alessia Pepe; Antonella Meloni; Giuseppe Rossi; Massimo Midiri; Massimiliano Missere; Gianluca Valeri; Francesco Sorrentino; Domenico Giuseppe D'Ascola; Anna Spasiano; Aldo Filosa; Liana Cuccia; Nicola Dello Iacono; Gianluca Forni; Vincenzo Caruso; Aurelio Maggio; Lorella Pitrolo; Angelo Peluso; Daniele De Marchi; Vincenzo Positano; John C Wood
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2018-03-01       Impact factor: 6.875

4.  Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major.

Authors:  P Kirk; M Roughton; J B Porter; J M Walker; M A Tanner; J Patel; D Wu; J Taylor; M A Westwood; L J Anderson; D J Pennell
Journal:  Circulation       Date:  2009-10-02       Impact factor: 29.690

Review 5.  Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review.

Authors:  Philip Haaf; Pankaj Garg; Daniel R Messroghli; David A Broadbent; John P Greenwood; Sven Plein
Journal:  J Cardiovasc Magn Reson       Date:  2016-11-30       Impact factor: 5.364

6.  Association between myocardial extracellular volume and strain analysis through cardiovascular magnetic resonance with histological myocardial fibrosis in patients awaiting heart transplantation.

Authors:  Yue Cui; Yukun Cao; Jing Song; Nianguo Dong; Xiangchuang Kong; Jing Wang; Yating Yuan; Xiaolei Zhu; Xu Yan; Andreas Greiser; Heshui Shi; Ping Han
Journal:  J Cardiovasc Magn Reson       Date:  2018-04-23       Impact factor: 5.364

Review 7.  CMR Parametric Mapping as a Tool for Myocardial Tissue Characterization.

Authors:  Vanessa M Ferreira; Stefan K Piechnik
Journal:  Korean Circ J       Date:  2020-08       Impact factor: 3.243

Review 8.  Myocardial fibrosis: why image, how to image and clinical implications.

Authors:  Rong Bing; Marc Richard Dweck
Journal:  Heart       Date:  2019-10-24       Impact factor: 5.994

9.  Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association.

Authors:  Dudley J Pennell; James E Udelson; Andrew E Arai; Biykem Bozkurt; Alan R Cohen; Renzo Galanello; Timothy M Hoffman; Michael S Kiernan; Stamatios Lerakis; Antonio Piga; John B Porter; John Malcolm Walker; John Wood
Journal:  Circulation       Date:  2013-06-17       Impact factor: 29.690

10.  Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance.

Authors:  Bernadette Modell; Maren Khan; Matthew Darlison; Mark A Westwood; David Ingram; Dudley J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2008-09-25       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.